COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
VORTO Welcomes Glenn Steinberg to its Advisory Board to Drive Innovation of its AI-Powered Trucking Logistics Platform
VORTO appoints Glenn Steinberg, EY's Global Supply Chain Leader, to Advisory Board to accelerate scaling operations across sectors with his extensive experience. CEO Priyesh Ranjan excitement for the innovative AI-powered freight trucking platform -
COMMUNIQUÉ DE PRESSE
Kingstone CEO Year-end Letter to Stockholders: Driving Growth and Increased Profitability
Kingstone Companies, Inc. issues Year-end Letter to Stockholders, highlighting record premium and profitability in 2024, strategic initiatives for growth in 2025, and debt prepayment for enhanced profitability -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: ABOUT YOU Holding SE: Chairman of the Supervisory Board continues in his office to accompany the Supervisory Board transition in the context of the takeover offer by Zalando
ABOUT YOU Holding SE's Chairman of the Supervisory Board, Mr. Sebastian Klauke, to continue in his role beyond April 30, 2025, in relation to the takeover offer by Zalando, ensuring a smooth transition in the Supervisory Board -
-
COMMUNIQUÉ DE PRESSE
Case IQ Acquires Lextegrity, Setting a New Standard for Compliance Management Solutions
Case IQ acquires Lextegrity to offer unified compliance and risk management solution enhancing real-time risk detection, workflows, and AI insights. Second acquisition in 15 months to disrupt the GRC category -
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
Jaguar Health, Inc. to participate in virtual fireside chat and in-person presentation at upcoming healthcare events. Focus on developing medicines from rainforest plants -
COMMUNIQUÉ DE PRESSE
Trans Canada Gold Corp. Ships 5,376 Barrels for December 2024 From Both Lloydminster Multilateral Heavy Oil Wells
Trans Canada Gold Corp. announces robust oil production for December 2024 and future drilling plans. Company focuses on responsible exploration for oil and gas assets in Canada -
COMMUNIQUÉ DE PRESSE
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
IGC Pharma, Inc. leverages geofencing technology to boost enrollment for Phase 2 CALMA trial addressing agitation in Alzheimer's disease. Advanced outreach tools enhance patient and caregiver engagement -
